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The first meeting dedicated to intestinal fibrosis, entitled The First International Summit on Fibrosis in Intestinal
Inflammation: Mechanisms and Biological Therapies, was held in Cleveland, Ohio, USA, on 28-29 September 2010.
Intestinal fibrosis is a complication of inflammatory conditions affecting the small and large bowel and often results
in serious clinical consequences. Despite its clinical importance, the study of inflammation-driven intestinal fibrosis
has received very limited attention. This explains why so little is known about its pathophysiology and the lack of
significant therapeutic advances, in contrast with the recent success achieved in controlling gut inflammation with
biological agents. The meeting covered most aspects directly relevant to intestinal fibrosis, including gut inflamma-
tion; cellular and molecular mechanisms of intestinal fibrogenesis; new clinical, diagnostic and prognostic tests and
novel therapeutic approaches.
Introduction
Intestinal fibrosis is common in chronic intestinal
inflammation as typically observed in both forms of
inflammatory bowel disease (IBD), Crohn’s disease and
ulcerative colitis. Fibrosis is a particularly frequent and
serious complication in Crohn’s disease, where it causes
clinically symptomatic narrowing of the lumen that often
requires surgical intervention. Unlike fibrosis involving
other organs, such as the liver and the lung, where
knowledge of the underlying pathogenic mechanisms is
more advanced, the study of intestinal fibrosis has
received very limited attention so far. This largely
explains the lack of understanding of its cause and
mechanisms and the exceedingly restricted and largely
ineffective therapeutic options available for medical ther-
apy. To improve this situation, generate new knowledge
and promote advances in this important clinical area, The
First International Summit on Fibrosis in Intestinal
Inflammation: Mechanisms and Biological Therapies was
held at the Cleveland Clinic, Cleveland, Ohio, USA, on
28-29 September 2010 (Additional file 1). The summit
was attended by approximately 90 participants from
t h eU S A ,E u r o p ea n dA s i a ,i n c l u d i n gs p e a k e r s ,y o u n g
investigators and a broad audience of basic investigators,
clinicians, gastroenterologists, surgeons and health-related
personnel.
Summary and Discussion
T h es u m m i tu n f o l d e do v e ra2 - d a yp e r i o da n dw a s
primarily focused on fibrosis of the small and large
intestine, with one session dedicated to liver fibrosis
and one session devoted to endoscopic approaches to
gastrointestinal strictures and chronic pancreatitis. In
the opening remarks, Dr. Victor Fazio (Digestive Dis-
ease Institute and Colorectal Surgery, Cleveland Clinic,
Cleveland, OH, USA) provided an overview of intest-
inal fibrosis from a clinical and surgical perspective,
underscoring the magnitude of the clinical problem,
the evolution of surgical techniques (strictureplasty) to
relieve stenotic lesions in Crohn’sd i s e a s e ,a n dt h e
urgent need to gain a better understanding of the
pathophysiology of stricture formation.
Session I was dedicated to the mechanisms and therapy
of inflammation. Dr. Claudio Fiocchi (Department of
Gastroenterology and Hepatology and Department of
Pathobiology, Cleveland Clinic) stressed the close interre-
lationship between chronic inflammation and intestinal
fibrosis and reviewed classical and novel cellular and
molecular mechanisms leading to activation of myofibro-
blasts, the primary culprits responsible for excessive
deposition of collagen and other extracellular matrix
(ECM) proteins in fibrotic conditions. Dr. Silvio Danese
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tas, Milan, Italy) discussed the increasingly appreciated
notion that intestinal inflammation is not the exclusive
result of immune activation, but instead the outcome of
complex interactions between immune and nonimmune
cells. In addition, Dr. Danese pointed out that an exag-
gerated emphasis on the role of the mucosal immune sys-
tem as the arbitrator of IBD can be detrimental to a
comprehensive and more realistic view of IBD pathogen-
esis and an explanation to the lack of attention given to
other cell types, particularly the mesenchymal cells
responsible for intestinal fibrosis. Dr. Georg Wick
(Laboratory of Autoimmunity, Innsbruck Medical Uni-
versity, Innsbruck, Austria) reviewed classical concepts of
immunology in the context of clinically relevant fibrotic
diseases, using as an example the fibrosis that develops
around silicone breast implants, with the local and sys-
temic consequences of this unique fibrotic response.
Similarities and differences with intestinal fibrosis were
discussed. Dr. Leonard Calabrese (Department of Rheu-
matic and Immunologic Diseases, Cleveland Clinic)
closed Session I with a broad overview of the develop-
ment, current use and future applications of biological
agents in the management of autoimmune and chronic
inflammation diseases, as well as the effect of such agents
on the fibrotic response that is often associated with
many of those conditions.
Session II was devoted to specific mechanisms of fibro-
genesis. Dr. Thomas Wynn (Immunopathogenesis Section,
National Institute of Allergy and Immunological Diseases,
National Institutes of Health, Bethesda, Maryland, USA)
initiated his talk by reminding the audience that almost
one-half of all natural deaths in the developed world
a r ea t t r i b u t a b l et of i b r o p r o l i f e r a t i v ed i s o r d e r s .H et h e n
reviewed recent evidence demonstrating that interleukin
(IL)-13 signaling through the IL-13Ra2i si n v o l v e di n
induction of TGF-b1 production and fibrosis and
discussed the distinct and overlapping roles for IL-13 and
IL-17 in murine S. mansoni- and bleomycin-induced liver
and pulmonary fibrosis models, respectively. The central
role of tumor growth factor (TGF)-b in fibrosis was briefly
reviewed by Dr. Rik Derynck (University of California San
Francisco, San Francisco, California, USA), who then ela-
borated in greater detail on the role of TGF-b in the intri-
guing but controversial topic of epithelial-to-mesenchymal
transition (EMT). EMT and related processes, such as
endothelial-to-mesenchymal transition (EndoMT), repre-
sent examples of processes in which nonmesenchymal cell
types are coerced into de novo collagen-producing cells
under immune and inflammatory pressure. This is con-
ceptually novel and challenges the conventional view that
only mesenchymal cells (fibroblasts, myofibroblasts, mus-
cle cells and stellate cells) produce excessive ECM during
af i b r o g e n i cr e s p o n s e .D r .S ubrata Ghosh (University of
Calgary, Calgary, Alberta, Canada) approached the chal-
lenging topic of whether TNF-a is a pro- or antifibrotic
agent. Some early reports claimed that Crohn’s disease
patients given the anti-tumor necrosis factor (TNF)-a
monoclonal antibody infliximab experienced worsening of
preexisting strictures. This led to the highly debated issue
of whether infliximab or other anti-TNF-a agents might
be contraindicated in Crohn’s disease patients carrying
important stenotic lesions. After a detailed review of the
literature, Dr. Ghosh concluded that current data do not
support the contention that intestinal stenosis, stricture or
obstruction are precipitated by such agents in the majority
of Crohn’s disease patients. Session II was concluded by
Dr. Donald Powell (The University of Texas Medical
Branch, Galveston, Texas, USA), who presented in depth
information on the intestinal myofibroblast; its multiple
sources (e.g., bone marrow stem cells, circulating fibro-
cytes and epithelial and endothelial cells); its diverse biolo-
gical functions in gut inflammation, repair and fibrosis;
and the possibility that intestinal myofibroblasts might be
a target for stem cell therapy.
The first day ended with Session III, which was dedi-
cated to presentations by young investigators, either junior
faculty members or fellows in training, who came to the
summit from the USA, Germany, The Netherlands, Italy,
Spain and Belgium. They presented ongoing research on a
variety of clinical and basic science topics related to intest-
inal fibrosis. These included new imaging modalities to
detect intestinal fibrosis in Crohn’s disease patients and
murine models of IBD, identification of transcription fac-
tors and cytokines involved in the S. typhimurium model
of inflammation-driven fibrosis, EndoMT in human and
experimental IBD, the imbalance of matrix metalloprotei-
nases (MMPs) and tissue inhibitor of metalloprotein-
ases (TIMPs), and the role of IL-10, IL-12/23(p40) and
IL-13Ra2 in murine schistosomiasis-associated liver fibro-
sis, the molecular mechanisms of acute chronic inflam-
mation and fibrosis in sepsis, the suppressive role of
the adipokine C1q/TNF-related protein-3 (CTRP-3) on
inflammatory and fibrotic responses of primary human
colonic fibroblasts and the role of eosinophils in murine
intestinal inflammation and remodeling.
The second day of the summit started with Session IV,
which centered on mechanisms of fibrogenesis in the
gastrointestinal tract. Opening this session, Dr. Thomas
Wight (Benaroya Research Institute and the University of
Washington, Seattle, Washington, USA) approached the
question whether the ECM is an active or passive player
in fibrosis. He presented evidence for the close reciprocal
relationship existing between cells and the surrounding
ECM, as well as its broad impact on cell adhesion, prolif-
eration, migration and survival. He went on by reminding
the audience that ECM changes leading to fibrosis are
common in several diseases and exemplified this by
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postmyocardial infarction scars and the differential bind-
ing of T cells and monocytes to different ECM compo-
nents. The topic of ECM continued with a presentation
by Dr. Carol de la Motte (Department of Pathobiology,
Cleveland Clinic) on the role of hyaluronan in inflamma-
tion in general and intestinal inflammation in particular.
Hyaluronan is rapidly produced upon tissue injury to
provide a temporary matrix to maintain structural integ-
rity, but upon its fragmentation size-specific fragments of
hyaluronan can be proinflammatory, and clearance of
hyaluronan is required for resolution of inflammation.
The direct relationship between hyaluronan and intest-
inal fibrosis remains a topic of further exploration.
Human and animal models of fibrogenesis in gut inflam-
mation were discussed by Dr. P. Kay Lund (University of
North Carolina at Chapel Hill, Chapel Hill, North Caro-
lina, USA). While fibrosis occurs in various intestinal
diseases, such as Crohn’s disease, ulcerative colitis, col-
lagenous colitis and radiation injury, human data are lim-
ited to descriptive studies describing the presence of
diverse mesenchymal cell types based on the expression
of a-smooth muscle actin, vimentin, desmin or c-kit.
More precise functional information can be derived from
animal models of experimental IBD and fibrosis, and
recently this field has received deserved attention with
the use of modified models of colitis (trinitrobenzene
sulfonic acid-, dextran sodium sulfate- and S. typhimur-
ium-induced and IL-10 deficiency) and ileocolitis
(peptidoglycan-polysaccharide [PGPS] -induced, senes-
cence-accelerated mouse P/Yit [SAMP/Yit], TNF-aΔ
ARE
and ileocolic resection in IL-10-deficient mice). Each
model has advantages and disadvantages, but these mod-
els do offer the distinct advantage of allowing the study
of gut fibrosis right after the triggering insult. Session IV
was closed by the presentation of Dr. Miquel Sans
(Hospital Clínic/IDIBAPS, Barcelona, Spain), who intro-
duced the concept of an imbalance between intestinal
fibroblast proliferation and apoptosis in IBD, which could
contribute to fibrogenesis in Crohn’s disease and ulcera-
tive colitis. In addition, he presented evidence that the
vitamin E derivates tocotrienols inhibit human intestinal
fibroblast proliferation and induce their apoptosis, possi-
bly though caspase 3- and 8-mediated mechanisms.
These effects could make tocotrienols suitable to prevent
or suppress intestinal fibrosis.
Clinical and therapeutic aspects of intestinal fibrosis
were discussed in Session V. Dr. Joseph Willis (Case
Western Reserve University, Cleveland, Ohio, USA)
reviewed the key pathological features of intestinal fibro-
sis in IBD and other conditions, underscoring that fibro-
s i si sp r e s e n tn o to n l yi nC r o h n ’sd i s e a s eb u ta l s o
ulcerative colitis, although it is usually limited to the
submucosal layer in the latter condition. New imaging
modalities to detect and localize fibrosis in the gastroin-
testinal tract were introduced by Dr. Ellen Zimmermann
(University of Michigan, AnnA r b o r ,M i c h i g a n ,U S A ) .
She went over what computed tomographic (CT) enter-
ography, magnetic resonance (MR) enterography, mag-
netization transfer magnetic resonance imaging and
ultrasound elastography can offer in the evaluation of
Crohn’s disease-affected bowel, pointing to the still
experimental nature of the techniques currently used.
The need and potential value of developing markers for
risk and outcomes in intestinal fibrosis were discussed
by Dr. Florian Rieder (Department of Gastroenterology
and Hepatology and Department of Pathobiology, Cleve-
land Clinic). Antibacterial antibodies, ECM proteins and
growth factors have been proposed as markers or pre-
dictors of fibrostenotic Crohn’s disease. While they are
promising tools, lack of specificity for fibrosis, fluctua-
tion over time and lack of prospective studies presently
limit their value and practical clinical applicability.
Dr. Shelia Violette (Stromedix, Inc., Cambridge, Massa-
chusetts, USA) presented information on the develop-
ment of a clinical biomarker strategy for fibrotic
diseases. The integrin avb6 is highly upregulated in
injured epithelial surfaces and leads to TGF-b activation
and, as such, represents an important mediator of fibro-
s i si no r g a n ss u c ha st h el i v e r ,k i d n e ya n dl u n g .A sa
result, avb6 could potentially serve as a marker of fibro-
sis but at the same time a target whose blockade could
inhibit TGF-b activation and relieve fibrosis. Closing
this session, Dr. Jane Onken (Duke University Medical
Center, Durham, North Carolina, USA) discussed stem
cell therapy for fibrosis by first enumerating properties
that may make them suitable for therapy, such as regu-
lation of the immune system, prevention of scar forma-
tion, formation of new vessels, homing to sites of injury
and induction of tissue regeneration. Clinical trials with
stem cells are under way in a variety of conditions,
including IBD. An open-label phase II trial of stem cell
therapy in Crohn’s disease showed a decrease of clinical
activity indices, some clinical responses and improve-
ment in quality of life. However, important challenges
remain to be addressed before a phase II trial can be
undertaken, including optimal dose, durability of
response, evidence of mucosal healing, biomarker avail-
ability and long-term safety.
Session VI was dedicated to liver fibrosis, an area far
more developed than intestinal fibrosis. Dr. Takao Sakai
(Department of Biomedical Engineering, Cleveland
Clinic) reviewed the animal models currently available
for study and modulation of experimental liver fibrosis,
with particular emphasis on the role of ECM proteins.
Dr. Massimo Pinzani (University of Florence School of
Medicine, Florence, Italy) gave a state-of-the-art overview
of current knowledge of the biology of hepatic stellate
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infection. The serious and present-day issue of wide-
spread obesity and its implications for insulin resistance
and liver fibrosis were examined by Dr. Laura Nagy
(Department of Pathobiology, Cleveland Clinic). She
emphasized the worldwide increasing prevalence of non-
alcoholic liver disease, obesity and fatty liver, as well as
the evolution from fatty liver to steatohepatitis to cirrho-
sis. She portrayed adipose tissue as a proinflammatory
system playing a major role in the pathogenesis of
hepatic fibrosis. Session VI continued with Dr. Jonathan
Fallowfield (University of Edinburgh, Edinburgh, UK),
who discussed therapeutic targets in liver fibrosis. Liver
cirrhosis is on the rise, and current antifibrotic
approaches should ideally be based on the treatment of
the underlying cause, but this is not always possible. No
antifibrotic agents are presently licensed in the USA or
Europe, but numerous agents are being experimentally
tested. These include caspase inhibitors, peroxisome pro-
liferator-activated receptor-g (PPAR-g)a g o n i s t ss u c ha s
pioglitazone, TGF-b blockers, colchicines, relaxin, adipo-
nectin, endothelin A, angiotensin receptor blockers, can-
nabinoids and alterations of the MMP-TIMP balance.
Many of the agents have been used in preclinical, phase I
or phase II trials; few trials are in phase III or IV, but
their clinically effectiveness remains to be established.
Last, Dr. Arthur McCullough (Department of Gastroen-
terology and Hepatology, Cleveland Clinic) reviewed
current indications of biological agents in nonalcoholic
fatty liver disease, a controversial area with limited
supporting evidence.
The summit concluded with Session VII devoted to
endoscopic or experimental approaches to management
of gastrointestinal strictures and chronic pancreatitis.
Although mechanical solutions do not provide definitive
solutions to biological problems, dilation of strictures, as
performed in esophageal lesions, biliary tree lesions and
IBD do provide significant clinical relief, as pointed out
by Dr. John Vargo and Dr. Bo Shen (both from the
Department of Gastroenterology and Hepatology,
Cleveland Clinic) and are well warranted. Finally, Dr.
Tyler Stevens (Department of Gastroenterology and
Hepatology, Cleveland Clini c )r e v i e w e dt h e r a p e u t i c
options for the management of fibrosis in chronic
pancreatitis. Various agents and procedures have been
proposed for this problematic clinical condition, ranging
from surgical or endoscopic interventions to immune
modulators, antioxidants, angiotensin receptor blockers,
PPAR-g ligands and herbal compounds.
Additional material
Additional file 1: Meeting announcement flyer. A single-page color
flyer announcing the First International Summit on Fibrosis in Intestinal
Inflammation: Mechanisms and Biological Therapies, its location, time of
year and contact information.
Author details
1Department of Gastroenterology & Hepatology, Digestive Disease Institute,
The Cleveland Clinic, Cleveland, OH, USA.
2Department of Pathobiology,
Lerner Research Institute, The Cleveland Clinic, Cleveland, OH, USA.
Authors’ contributions
Both authors contributed equally to the conception and writing of the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2010 Accepted: 11 November 2010
Published: 11 November 2010
doi:10.1186/1755-1536-3-22
Cite this article as: Rieder and Fiocchi: First international summit on
fibrosis in intestinal inflammation: mechanisms and biological therapies.
Fibrogenesis & Tissue Repair 2010 3:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rieder and Fiocchi Fibrogenesis & Tissue Repair 2010, 3:22
http://www.fibrogenesis.com/content/3/1/22
Page 4 of 4